Infectiologic differential diagnosis of chronic Lyme disease and so ...

More documents

Recommendations

Info

[43] Bakken JS, Krueth JK, Lund T, Malkovitch D, Asanovich K, Dumler JS. Exposure to deer blood may be a cause of human granulocytic ehrlichiosis. Clin Infect Dis 1996; 23(1): 198. [44] Krause PJ, Wormser GP. Nosocomial transmission of human granulocytic anaplasmosis? JAMA 2008; 300(19): 2308-9. [45] Dumler JS, Bakken JS. Ehrlichial diseases of humans: emerging tick-borne infections. Clin Infect Dis 1995; 20(5): 1102-10. [46] Dawson JE, Fishbein DB, Eng TR, Redus MA, Green NR. Diagnosis of human ehrlichiosis with the indirect fluorescent antibody test: kinetics and specificity. J Infect Dis 1990; 162(1): 91-5. [47] Brouqui P, Bacellar F, Baranton G et al. Guidelines for the diagnosis of tickborne bacterial diseases in Europe. Clin Microbiol Infect 2004; 10(12): 1108- 32. [48] Bakken JS, Haller I, Riddell D, Walls JJ, Dumler JS. The serological response of patients infected with the agent of human granulocytic ehrlichiosis. Clin Infect Dis 2002; 34(1): 22-7. [49] Bakken JS, Dumler JS. Ehrlichiosis and anaplasmosis. Infect Med 2004; 21:433. [50] Paddock CD, Childs JE. Ehrlichia chaffeensis: a prototypical emerging pathogen. Clin Microbiol Rev 2003; 16(1): 37-64. [51] Bakken JS, Krueth J, Wilson-Nordskog C, Tilden RL, Asanovich K, Dumler JS. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 1996; 275(3): 199-205. 64
[52] Bakken JS, Aguero-Rosenfeld ME, Tilden RL et al. Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis. Clin Infect Dis 2001; 32(6): 862-70. [53] Chapman AS, Bakken JS, Folk SM et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichiosis, and anaplasmosis - - United States: a pracitcal guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4): 1-27. [54] Standaert SM, Yu T, Scott MA et al. Primary isolation of Ehrlichia chaffeensis from patients with febrile illnesses: clinical and molecular characteristics. J Infect Dis 2000; 181(3): 1082-8. [55] Felek S, Unver A, Stich RW, Rikihisa Y. Sensitive detection of Ehrlichia chaffeensis in cell culture, blood, and tick specimens by reverse transcription- PCR. J Clin Microbiol 2001; 39(2): 460-3. [56] Walls JJ, Caturegli P, Bakken JS, Asanovich KM, Dumler JS. Improved sensitivity of PCR for diagnosis of human granulocytic ehrlichiosis using epank1 genes of Ehrlichia phagocytophila-group ehrlichiae. J Clin Microbiol 2000; 38(1): 354-6. [57] Vannier E, Gewurz BE, Krause PJ. Human babesiosis. Infect Dis Clin North Am 2008; 22(3): 469-88. [58] Zintl A, Mulcahy G, Skerrett HE, Taylor SM, Gray JS. Babesia divergens, a bovine blood parasite of veterinary and zoonotic importance. Clin Microbiol Rev 2003; 16(4): 622-36. [59] Leiby DA. Babesiosis and blood transfusion: flying under the radar. Vox Sang 2006; 90(3): 157-65. 65
Page 1 and 2:
Infectiologic differential diagnosi
Page 3 and 4:
3 Anamnistically, one has to consid
Page 5 and 6:
Table 2 LD coinfections (not tick-b
Page 7 and 8:
Table 5 Bartonellosis’ infection
Page 9 and 10:
Table 6 Main disease manifestations
Page 11 and 12:
11 Fig. 1. Erythrocytes infected wi
Page 13 and 14: 13 Bartonellae are localized in ery
Page 15 and 16: ESR und CRP elevated Hypercalcemia
Page 18 and 19: Table 9 Antibiotic treatment of bar
Page 20 and 21: antibiosis is that the antibiotic i
Page 22 and 23: The laboratory diagnostics for Chla
Page 24 and 25: The arthritis occurs in 1% of the u
Page 26 and 27: In the differential diagnosis of Ly
Page 28 and 29: Late phase: - Reactive arthritis -
Page 30 and 31: the depiction of chronic yersiniosi
Page 32 and 33: In Yersinia-PCR-positive patients,
Page 34 and 35: - Incubation period 3 weeks - Atypi
Page 36 and 37: system, of the skin and other organ
Page 38 and 39: - Ehrlichia chaffeensis [1] - Anapl
Page 40 and 41: Since seroprevalence merely express
Page 42 and 43: B. microti is the predominant patho
Page 44 and 45: epresent a major health hazard and
Page 46 and 47: The decisive diagnostic information
Page 48 and 49: Probable: IFA IgG 1:1024 and one of
Page 50 and 51: The main manifestation of the Campy
Page 52 and 53: The term “reactive arthritis” i
Page 54 and 55: In the diagnosis of a “reactive a
Page 56 and 57: Table 27 Disease manifestations of
Page 58 and 59: addition, other pathogens discussed
Page 60 and 61: [8] Schouls LM, Van De Pol I, Rijpk
Page 62 and 63: [25] Hermanowska-Szpakowicz T, Skot
Page 66 and 67: [60] Fox LM, Wingerter S, Ahmed A e
Page 68 and 69: [80] Marra CM. Neurologic complicat
Page 70 and 71: [100] Pulliainen AT, Dehio C. Barto
Page 72 and 73: [118] Bass JW, Freitas BC, Freitas
Page 74 and 75: [137] Gaydos CA, Roblin PM, Hammers
Page 76 and 77: [155] Cover TL, Aber RC. Yersinia e
Page 78 and 79: multi-organ donors for the presence
Page 80 and 81: [190] Straubinger RK, Straubinger A
Page 82 and 83: [208] Bitnun A, Ford-Jones E, Blase
Page 84 and 85: patients with reactive and undiffer
Page 86 and 87: [242] Appelbaum PC, Gillespie SH, B
Page 88 and 89: pneumoniae infection associated wit
Page 90 and 91: [276] Thomas NH, Collins JE, Robb S
Page 92 and 93: [294] File TM Jr, Segreti J, Dunbar
Page 94 and 95: [310] Sorvillo FJ, Lieb LE, Waterma
Page 96 and 97: henselae Isolates Collected from Ca
Page 98 and 99: [345] Raoult D, Levy PY, Harlé JR,
show all

Infectiologic differential diagnosis of chronic Lyme disease and so ...

Create successful ePaper yourself

Delete template?

Save as template?